Dr. Shohei Koide, Professor of Biochemistry and Molecular Pharmacology at New York University Grossman School of Medicine, and Director of Cancer Biologics at Perlmutter Cancer Center at NYU Langone Health, was inducted into the 2022 Class of Fellows of the National Academy of Inventors, the highest professional distinction awarded to academic inventors. NAI-Fellows include 51 Nobel laureates and 63 recipients of the U.S. National Medal of Technology and Innovation and U.S. National Medal of Science. Japanese NAI-Fellows include Prof. Shuji Nakamura 2014 (UC Santa Barbara, Nobel Prize in Physics in 2014), Prof. Iwao Ojima 2014 (SUNY Stony Brook), and Prof. Shohei Koide 2022 (NYU). Dr. Koide is a leader in protein engineering and design, and has made fundamental contributions to the establishment and advancement of the field of synthetic binding protein development and its application in biology and medicine. Learn more about his research at his profile on the NYU website. Dr. Koide holds 30 granted and 20 pending US patents in the field of biotechnology, 35 of which have been licensed. Two of his therapeutic programs have advanced to clinical trials. In 2022, Dr. Koide co-founded Aethon Therapeutics which develops a new therapeutic strategy to effectively kill drug-resistant cancers. He also co-founded Revalia Bio, an early-stage startup company which formulates a new model of drug development using monobody technology.
